Evidence map›Paper›PMID 32724342›Full record

ArticleOncology letters2020

Expression of anti-apoptotic protein survivin in human endometrial carcinoma: Clinical and pathological associations as a separate factor and in combination with concomitant PTEN and p53 expression.

Aggelis Stavropoulos, Michail Varras, Thivi Vasilakaki, Viktoria-Konstantina Varra, Fani-Niki Varra, Aikaterini Tsavari, Aphrodite Nonni, Nikolaos Kavantzas, Andreas C Lazaris

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Aggelis StavropoulosForth Obstetrics and Gynecology Department, 'Elena Venizelou' General Hospital, Athens 11521, Greece.
Michail VarrasFifth Obstetrics and Gynecology Department, 'Elena Venizelou' General Hospital, Athens 11521, Greece.
Thivi VasilakakiDepartment of Pathology, 'Tzaneio' General Hospital, Piraeus 18536, Greece.
Viktoria-Konstantina VarraDepartment of Pharmacy, University of Patras, Patra 26504, Greece.
Fani-Niki VarraDepartment of Pharmacy, Frederick University, Nicosia 1036, Cyprus.
Aikaterini TsavariDepartment of Pathology, 'Tzaneio' General Hospital, Piraeus 18536, Greece.
Aphrodite NonniFirst Pathology Department, Medical School, National Kapodistrian University, Athens 11527, Greece.
Nikolaos KavantzasFirst Pathology Department, Medical School, National Kapodistrian University, Athens 11527, Greece.
Andreas C LazarisFirst Pathology Department, Medical School, National Kapodistrian University, Athens 11527, Greece.
National and Kapodistrian University of Athens · GRGeneral-Maternity District Hospital Helena Venizelou · GRTzaneion General Hospital · GRFrederick University · CYUniversity of Patras · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial carcinoma is one of the most common types of gynecological cancer. A total of 99 cases of primary endometrial carcinoma were investigated for survivin expression by immunohistochemistry. Furthermore, the association between concomitant survivin, PTEN and p53 expression, and clinicopathological parameters was examined. Immunopositivity for survivin was identified in 88% of cases. Concomitant survivin, PTEN and p53 expression (staining scores and intensity) was observed in 60% of endometrial adenocarcinomas. A significant association was identified between the sum of staining intensity and scores of survivin immunopositive cells, and patient age (P=0.028), histological grade (P<0.001), clinical stage (P=0.018) and fallopian tube and/or ovarian invasion (P=0.039). A negative tendency for correlation was observed between surivin and PTEN immunostaining scores (P=0.062; ρ=-0.238). Specimens with high scores of survivin expression tended to show decreased scores of PTEN immunostaining, and vice versa. However, in circumstances with an increased co-expression of survivin and PTEN, a statistically significant association with histological types was observed (P=0.020). A statistically significant positive correlation was identified between survivin and p53 sum co-expression (P=0.008; ρ=0.300). Furthermore, a significant association was identified between survivin and p53 concomitant sum expression and age of patients (P=0.001), histological type (P=0.020), clinical stage (P=0.037), histological differentiation (P=0.001) and presence of fallopian tube and/or ovarian invasion (P=0.026). The present findings suggested that survivin may be an indicator of unfavorable outcome in older patients with endometrial carcinoma, in specific circumstances that are dependent on different concomitant genetic alterations and different combinations of molecular signaling pathways. Increased expression levels of survivin and PTEN may serve a role in the development of more aggressive endometrial carcinoma during their interaction. In addition, protein expression levels of survivin and p53 are positively correlated and may share a common molecular pathway to promote endometrial carcinogenesis. These findings provided evidence that survivin and p53 combined may be useful markers for the prediction of tumor behavior and prognosis.

Indexed as

carcinomaconcomitantendometrialexpressionimmunohistochemistrymolecular pathologyp53PTENsurvivin

Identifiers

PMID32724342
PMCPMC7377108
OpenAlexW3030319833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.